CA1048931A - Bacterial antigen composition for treatment of oto-rhinolaringological infections - Google Patents
Bacterial antigen composition for treatment of oto-rhinolaringological infectionsInfo
- Publication number
- CA1048931A CA1048931A CA75234882A CA234882A CA1048931A CA 1048931 A CA1048931 A CA 1048931A CA 75234882 A CA75234882 A CA 75234882A CA 234882 A CA234882 A CA 234882A CA 1048931 A CA1048931 A CA 1048931A
- Authority
- CA
- Canada
- Prior art keywords
- staphylococcus aureus
- antigenic
- weight
- streptococcus
- fractions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 230000001580 bacterial effect Effects 0.000 title claims description 9
- 238000011282 treatment Methods 0.000 title abstract description 15
- 208000015181 infectious disease Diseases 0.000 title abstract description 7
- 239000000427 antigen Substances 0.000 title description 10
- 108091007433 antigens Proteins 0.000 title description 10
- 102000036639 antigens Human genes 0.000 title description 10
- 230000000890 antigenic effect Effects 0.000 claims abstract description 88
- 241000191967 Staphylococcus aureus Species 0.000 claims abstract description 32
- 241000194017 Streptococcus Species 0.000 claims abstract description 23
- 241000193998 Streptococcus pneumoniae Species 0.000 claims abstract description 22
- 241000588653 Neisseria Species 0.000 claims abstract description 19
- 241000193996 Streptococcus pyogenes Species 0.000 claims abstract description 19
- 230000009089 cytolysis Effects 0.000 claims abstract description 14
- 108090000526 Papain Proteins 0.000 claims abstract description 11
- 239000004365 Protease Substances 0.000 claims abstract description 11
- 102000004142 Trypsin Human genes 0.000 claims abstract description 11
- 108090000631 Trypsin Proteins 0.000 claims abstract description 11
- 230000002255 enzymatic effect Effects 0.000 claims abstract description 11
- 229940055729 papain Drugs 0.000 claims abstract description 11
- 235000019834 papain Nutrition 0.000 claims abstract description 11
- 239000012588 trypsin Substances 0.000 claims abstract description 11
- 235000015097 nutrients Nutrition 0.000 claims abstract description 9
- 238000009826 distribution Methods 0.000 claims abstract description 6
- 239000002609 medium Substances 0.000 claims description 35
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 26
- 238000000034 method Methods 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 16
- 239000007788 liquid Substances 0.000 claims description 13
- 239000011780 sodium chloride Substances 0.000 claims description 13
- 239000001963 growth medium Substances 0.000 claims description 12
- 239000007787 solid Substances 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 9
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical class N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 6
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 6
- 239000012153 distilled water Substances 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000001888 Peptone Substances 0.000 claims description 3
- 108010080698 Peptones Proteins 0.000 claims description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 claims description 3
- 229910000387 ammonium dihydrogen phosphate Inorganic materials 0.000 claims description 3
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229910000396 dipotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019797 dipotassium phosphate Nutrition 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 229910052500 inorganic mineral Chemical class 0.000 claims description 3
- 239000007791 liquid phase Substances 0.000 claims description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 3
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 3
- 239000011702 manganese sulphate Substances 0.000 claims description 3
- 235000007079 manganese sulphate Nutrition 0.000 claims description 3
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 3
- 239000011707 mineral Chemical class 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 235000019837 monoammonium phosphate Nutrition 0.000 claims description 3
- 239000006012 monoammonium phosphate Substances 0.000 claims description 3
- 229910000402 monopotassium phosphate Inorganic materials 0.000 claims description 3
- 235000019796 monopotassium phosphate Nutrition 0.000 claims description 3
- 235000001968 nicotinic acid Nutrition 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 239000011664 nicotinic acid Substances 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 235000019319 peptone Nutrition 0.000 claims description 3
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 claims description 3
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960004172 pyridoxine hydrochloride Drugs 0.000 claims description 3
- 235000019171 pyridoxine hydrochloride Nutrition 0.000 claims description 3
- 239000011764 pyridoxine hydrochloride Substances 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 235000019192 riboflavin Nutrition 0.000 claims description 3
- 239000002151 riboflavin Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 229960000344 thiamine hydrochloride Drugs 0.000 claims description 3
- 235000019190 thiamine hydrochloride Nutrition 0.000 claims description 3
- 239000011747 thiamine hydrochloride Substances 0.000 claims description 3
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- 239000003610 charcoal Substances 0.000 claims 4
- 230000000415 inactivating effect Effects 0.000 claims 1
- 239000007922 nasal spray Substances 0.000 claims 1
- 229940097496 nasal spray Drugs 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 238000004108 freeze drying Methods 0.000 abstract description 4
- 238000000746 purification Methods 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 15
- 241000700159 Rattus Species 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000941 anti-staphylcoccal effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000700198 Cavia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000005141 Otitis Diseases 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 206010039083 rhinitis Diseases 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- 101000795130 Homo sapiens Trehalase Proteins 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 102100029677 Trehalase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000001459 mortal effect Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940076156 streptococcus pyogenes Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
- A61K39/092—Streptococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB38984/74A GB1518277A (en) | 1974-09-06 | 1974-09-06 | Antigenic composition |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1048931A true CA1048931A (en) | 1979-02-20 |
Family
ID=10406910
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA75234882A Expired CA1048931A (en) | 1974-09-06 | 1975-09-05 | Bacterial antigen composition for treatment of oto-rhinolaringological infections |
Country Status (13)
Country | Link |
---|---|
JP (1) | JPS5161624A (es) |
AR (1) | AR205836A1 (es) |
BE (1) | BE832959A (es) |
CA (1) | CA1048931A (es) |
CH (1) | CH606437A5 (es) |
DE (1) | DE2539622A1 (es) |
DK (1) | DK394075A (es) |
ES (1) | ES440773A1 (es) |
FR (1) | FR2283697A1 (es) |
GB (1) | GB1518277A (es) |
IL (1) | IL48066A (es) |
NL (1) | NL7510575A (es) |
SE (1) | SE7509913L (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH633188A5 (fr) * | 1978-05-26 | 1982-11-30 | Om Laboratoires Sa | Medicament contre des maladies infectieuses des voies respiratoires. |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1553099A (es) * | 1967-11-30 | 1969-01-10 |
-
1974
- 1974-09-06 GB GB38984/74A patent/GB1518277A/en not_active Expired
-
1975
- 1975-01-01 AR AR260277A patent/AR205836A1/es active
- 1975-09-01 FR FR7526754A patent/FR2283697A1/fr active Granted
- 1975-09-01 BE BE159649A patent/BE832959A/xx unknown
- 1975-09-02 DK DK394075A patent/DK394075A/da unknown
- 1975-09-05 SE SE7509913A patent/SE7509913L/xx unknown
- 1975-09-05 CH CH1153975A patent/CH606437A5/xx not_active IP Right Cessation
- 1975-09-05 CA CA75234882A patent/CA1048931A/en not_active Expired
- 1975-09-05 DE DE19752539622 patent/DE2539622A1/de not_active Withdrawn
- 1975-09-05 IL IL48066A patent/IL48066A/xx unknown
- 1975-09-05 ES ES440773A patent/ES440773A1/es not_active Expired
- 1975-09-06 JP JP50108452A patent/JPS5161624A/ja active Pending
- 1975-09-08 NL NL7510575A patent/NL7510575A/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
FR2283697B1 (es) | 1979-03-23 |
DK394075A (da) | 1976-03-07 |
NL7510575A (nl) | 1976-03-09 |
JPS5161624A (es) | 1976-05-28 |
SE7509913L (sv) | 1976-03-08 |
AR205836A1 (es) | 1976-06-07 |
DE2539622A1 (de) | 1976-03-18 |
BE832959A (fr) | 1976-03-01 |
ES440773A1 (es) | 1977-03-16 |
IL48066A0 (en) | 1975-11-25 |
GB1518277A (en) | 1978-07-19 |
CH606437A5 (es) | 1978-11-30 |
FR2283697A1 (fr) | 1976-04-02 |
IL48066A (en) | 1978-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Belton et al. | Studies on a protective antigen produced in vitro from Bacillus anthracis: medium and methods of production | |
RU2194531C2 (ru) | Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно (акдс)-полиомиелитные вакцины | |
CA1231643A (en) | Composition of intravenous immune globulin | |
EP0648127B1 (en) | Type i surface antigens associated with staphylococcus epidermidis | |
JPH04501429A (ja) | ウイルスで汚染された薬理組成物中のウイルスの不活性化方法 | |
WO2017006349A1 (en) | Polysaccharide vaccine formulations and processes for industrial production of bacterial polysaccharides | |
JPH05506649A (ja) | 百日咳菌外膜蛋白質の精製方法 | |
EP1748063B1 (en) | Protein A production and purification without using animal derived components | |
NZ566871A (en) | Protein A Production and Purification without Using Animal Derived Components involving staphylococcus aureus | |
US20220267419A1 (en) | Human Immunoglobulin Against Methicillin-Resistant Staphylococcus Aureus, Preparation Method Therefor, And Use Thereof | |
KR100401423B1 (ko) | 혼합 백신의 제조 방법 | |
US4349540A (en) | Process for preparing vaccines based on antigenic ribosomal fractions | |
EP0691348A1 (en) | Immunogenic compositions prepared from adenylate cyclase of B. Parapertussis | |
DD202623A5 (de) | Verfahren zur herstellung von sporen-polyosiden | |
CA1048931A (en) | Bacterial antigen composition for treatment of oto-rhinolaringological infections | |
KR0169982B1 (ko) | 피부염 치료용 약제 | |
US5225194A (en) | Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases | |
PL126416B1 (en) | Method of obtaining immunobiotherapeutic preparation counteractive against respiratory system diseases | |
CA1117866A (en) | Haemophilus influenzae vaccine | |
UA121358C2 (uk) | Інактивована стафілококова рідка вакцина, спосіб її виготовлення і спосіб лікування та профілактики нею | |
RU2533815C1 (ru) | Способ получения протективной белоксодержащей фракции бактерий | |
KR970001707B1 (ko) | 약독화 녹농균주 cfcpa 50243을 이용한 녹농균 감염 예방 백신 | |
Burans et al. | Kinetics of Haemophilus influenzae type B infection in normal and ribosome-immunized mice using intraperitoneal and intracerebral routes of inoculation. | |
KR100250714B1 (ko) | 녹농균 감염증 치료제 | |
KR970001704B1 (ko) | 약독화 녹농균주 cfcpa 20215를 이용한 녹농균 감염 예방 백신 |